Jungbauer C G, Maier L S
Klinik und Poliklinik für Innere Medizin II, Universitätsklinikum Regensburg, 93053, Regensburg, Deutschland.
Herzschrittmacherther Elektrophysiol. 2019 Sep;30(3):262-267. doi: 10.1007/s00399-019-00635-0. Epub 2019 Aug 23.
Acquired QT prolongation is almost exclusively the result of inhibition of the potassium channel Ikr. Especially hospitalized patients have a high risk to suffer from Torsade de points (TdP). Therefore, any prescription of drugs with the potential for QT prolongation should involve the consideration of the necessity of the agent and interaction with other QT prolonging drugs. The website www.crediblemed.com helps to identify the risk for TdP of each drug. During drug prescription, it is necessary to monitor QTc with regular ECGs; QTc prolongation >500 ms or QTc increase >60 ms should trigger end of drug administration followed by monitoring of the patient according to the individual risk for TdP.
获得性QT间期延长几乎完全是钾通道Ikr受抑制的结果。尤其是住院患者发生尖端扭转型室速（TdP）的风险很高。因此，任何有可能延长QT间期的药物处方都应考虑该药物的必要性以及与其他可延长QT间期药物的相互作用。网站www.crediblemed.com有助于识别每种药物发生TdP的风险。在药物处方过程中，有必要定期进行心电图检查以监测QTc；QTc延长>500毫秒或QTc增加>60毫秒应促使停止用药，随后根据患者发生TdP的个体风险进行监测。
